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Introduction: Currently, the inhibitor of the epidermal growth
factor receptor tyrosine kinase erlotinib is widely used for the
treatment of non-small cell lung cancer. Patients with a mutation or
deletion in the epidermal growth factor receptor gene will benefit
most and are likely to receive the drug for long periods and willing
to accept side effects if responding.
Methods: Twenty-two cases with prolonged administration of erlo-
tinib (at least 6 months) and side effects are reported. Three cases
with specific side effects are described in detail.
Results: In addition to the well-known side effects such as follicu-
litis and diarrhea, patients reported paronychia, fatigue, and hair
changes.
Discussion: After prolonged administration of erlotinib in most
patients, the initial side effects persist while other inconvenient ones
may develop. This may lead to dose reductions or even cessation of
treatment.
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The inhibitor of the epidermal growth factor receptor(EGFR) tyrosine kinase erlotinib became widely used
after demonstrated efficacy in second- or third-line treatment
of non-small cell lung cancer.1 Because of the limited activity
in the majority of the population, most patients were only
treated for a few months, and therefore, mainly acute side
effects were reported. This is different for patients with an
activating mutation in the EGFR gene. Because these patients
are likely to have major responses, they will receive EGFR
tyrosine kinase inhibitors (TKIs) for a substantial period of
time.2 EGFR TKIs are associated with lower incidences of
alopecia, nausea, vomiting, neurotoxic symptoms, and myelo-
suppression compared with platinum-based chemotherapy.2
Common side effects of EGFR TKIs are folliculitis, diarrhea,
dry skin, and fatigue.1 Especially when there is a good
response on treatment, patients intend to consider these side
effects as tolerable. However, after months or years of treat-
ment, some side effects may aggravate and new symptoms
may occur. This may even lead to dose reduction or even
premature cessation of effective therapy. In this report, we
describe side effects in patients treated for more than 6
months and illustrate some of the long-term side effects of
EGFR TKIs in three patients who used erlotinib for 6 months
to 4.5 years.
CASE HISTORY 1
A 61-year-old Chinese woman, never smoker, pre-
sented with cognitive disturbances and coordination prob-
lems. She was diagnosed with adenocarcinoma in the right
lung with two brain metastases (T2N0M1). Seven years
earlier, she was treated for an adenocarcinoma in the breast.
However, histology of the current lung tumor was different.
Mutational analysis demonstrated the L858R point mu-
tation in EGFR exon 21. She was treated with whole brain
and stereotactic radiotherapy. Because of a hydrocephalus,
she also received a ventriculoperitoneal drain. Thereafter, 150
mg erlotinib once a day was started. Two weeks later, she
developed folliculitis grade 1 of her face and diarrhea grade
1. A computer tomography (CT) scan after 6 weeks showed
a significant regression of the lung tumor, and therefore,
erlotinib was continued. After 5 months of treatment, the
folliculitis of her face still existed but was considered too
mild to treat. In addition, she showed a paronychia of the
right big toe (Figure 1). Erlotinib was discontinued, and the
paronychia was treated with fucidin ointment. Ten days later,
the folliculitis had resolved, and erlotinib was started again at
a dose of 100 mg once a day. Two months later with a
persistent response of the lung tumor, the folliculitis had not
recurred, but walking was still painful because the paronychia
did not recover with conservative treatment.
CASE HISTORY 2
In October 2008, a 29-year-old woman with a 1-year
smoking history was diagnosed with malignant pleural effu-
sion of the right hemithorax and an adenocarcinoma in the
right lung (T4N3M1). Massive pulmonary embolism was
also found and treated with low molecular weight heparin.
Mutational analysis demonstrated a deletion in EGFR
exon 19. She commenced with 150 mg erlotinib once a day.
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One week later, her face and thorax showed an acneiform
rash. Six weeks after treatment, her pulmonary tumor re-
gressed, and she felt good despite the folliculitis; therefore,
erlotinib was continued. The dermatologist prescribed corti-
costeroid ointment and doxycycline for 6 weeks with good
results.
In July 2009, she complained of pain in the hair roots,
an extremely dry skin and dry eyes. On her head, androgen-
like frontal alopecia was visible (Figure 2), whereas hair
growth on her hands, arms, and eyelashes was increased. The
keratoconjunctivitis sicca was treated with methylcellulose
drops. Furthermore, walking was painful because of a paro-
nychia of the right big toe. This was treated with fucidin
ointment, and the erlotinib dose was decreased to 100 mg
once a day.
In October 2009, after 1-year treatment with erlotinib,
her skin problems were tolerable, but she still had difficulty
on walking because of paronychia. Inflammation had also
started on her left toe. She was referred to the surgeon who
made a wedge incision (Figure 3).
CASE HISTORY 3
In April 2005, 50-year-old man, never smoker, started
with 150 mg erlotinib once a day because of a stage IV
adenocarcinoma due to malignant pleural effusion of the right
lung. In 2000, he was diagnosed, in another hospital, with an
adenocarcinoma in the right upper lobe and underwent a
lobectomy. In 2002, metastasectomy of an assumed solitary
rib metastasis was performed followed within 1 year by
chemoradiation for local recurrence. In 2004, he again had a
local recurrence together with malignant pleural effusion.
After two cycles of platinum-based chemotherapy, progres-
sion was found, and after referral to our center, erlotinib was
started in April 2005.
After 6 weeks, partial remission was seen on CT scan,
he felt quite good, despite a folliculitis grade 1, and erlotinib
was continued. After 8 months, he complained of progressive
fatigue and very dry eyes. The latter symptom was tolerable
with a topical gel.
One year later, he was still using erlotinib because of
persistent response, and mutation analysis of the previously
resected primary tumor was performed and showed a muta-
tion in EGFR exon 19. He was still suffering from dry eyes,
a folliculitis grade 1, diarrhea grade 1, and an itching throat;FIGURE 1. Case 1: paronychia of the right big toe.
FIGURE 2. Case 2: hair before (left) and
after (right) erlotinib treatment: androgen-
like frontal alopecia.
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however, severe fatigue had the largest impact on his quality
of life.
In May 2009, there were still no signs of progression.
However, after 4 years of erlotinib use, he had the same side
effects, except the itching throat. In addition, he had devel-
oped erectile dysfunction, for which sildenafil was pre-
scribed. Unfortunately, the extreme fatigue reduced the qual-
ity of life to such a degree that discontinuation of erlotinib
was decided. Other causes of fatigue than erlotinib, such as
anemia, electrolyte disturbances, Lyme disease, and hypothy-
roidism, had been excluded. After 1 week, he complained of
pain in his right hemithorax for which morphine was
needed to get adequate relieve. In September, an intermit-
tent cough evolved, whereas the fatigue had improved. In
December 2009, local tumor recurrence was demonstrated
by CT scan and histology. Erlotinib was reintroduced at a
lower dose of 100 mg once a day. Unfortunately, fatigue
returned, but he was motivated to tolerate it because of the
disease progression.
From 22 patients who received erlotinib for more than
6 months, we scored the side effects as reported in the patient
files (Table 1). Mostly reported were folliculitis, diarrhea,
keratoconjunctivitis, and fatigue. Paronychia and stomatitis
were also reported in a significant number of patients. Fifty
percent of patients eventually had a dose reduction because of
intolerable side effects.
DISCUSSION
Here, we describe long-term side effects in three pa-
tients receiving erlotinib for adenocarcinoma in the lung. All
three had an activating mutation of the EGFR gene. In view
of good tumor response on this EGFR TKI treatment, patients
and their treating physicians were highly motivated to con-
tinue therapy. Therefore, early and continuing side effects
such as folliculitis and diarrhea were considered bearable. In
all cases, skin toxicity persisted. In case 2, the folliculitis
resolved, but a very dry skin (xerosis cutis) occurred instead.
The folliculitis in case 3 was still present after 4.5 years of
treatment. In addition, diarrhea persisted in cases 1 and 3.
Also, some symptoms such as paronychia, brittle hair, erec-
tile dysfunction, and keratoconjunctivitis sicca occurred only
after long-term treatment, and the latter three symptoms
developed even after a year. Finally, in case 3, fatigue was
increasingly a problem, eventually leading to drug discontin-
uation and subsequently lung cancer progression.
In the Table 1, long-term side effects among 22 pa-
tients, who received erlotinib for at least 6 months, are
shown. It illustrates that most side effects were just grade 1 or
2, but because these usually persist, this may become intol-
erable. Eleven patients (50%) eventually received a dose
reduction because of these side effects.
Several publications addressed the management of
TKI-related skin toxicity.3,4 We treated patients according to
the recommendations of Galimont-Collen et al.4 In addition,
we administered loperamide for diarrhea and topical eye gel
or drops for the keratoconjunctivitis sicca. Unfortunately, the
paronychia often does not heal with conservative treatment,
TABLE 1. Side Effects among 22 Patients Who Received
Erlotinib for More Than 6 mo





Dose reduction in months,
mean (range)
15 (6–31)*
Folliculitis 16 11 5
Diarrhea 11 11 0
Fatigue 8 7 1
Paronychia 4 1 3
Hair loss and hair changes 3 4 0
Keratoconjunctivitis sicca 6 5 1
Chronic cough 5 5 0
Stomatitis 4 4 0
EGFR, epidermal growth factor receptor.
*Among 11 patients.
FIGURE 3. Case 2: paronychia of the right big toe, and the
interdigital skin is also inflamed.
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and surgical treatment is necessary. Even this procedure may
not be sufficient to walk normally again.
Erlotinib-associated skin toxicity occurs in virtually all
patients who have been treated for more than 6 months,
although the clinical skin spectrum changes.5 This may be
explained by the fact that EGFR is not only present in the
lung tumor but also present in the skin. The EGFR-signaling
cascade is involved in biology of the keratinocytes in the
epidermis and the homeostasis of the hair follicles.4 Inter-
rupting this pathway leads to disorganization of the follicles
in the seborrhoeic areas of the skin. This may lead to
folliculitis, xerosis cutis, brittle hair, and paronychia.4 Most
likely, it also causes the keratoconjunctivitis sicca. Paro-
nychia is an inflammation of the nail fold, which is difficult
to treat and very disabling. A possible mechanism is chronic
irritation of the thinned periungual tissue by the nail.6 This
may present as ingrown nails and often need surgical inci-
sion. Finally, there is no clear mechanism explaining the
erectile dysfunction and severe fatigue. These symptoms may
fit in with depression. TKI-associated depression has been
reported before; however, no pathophysiologic mechanism
was provided.7 In all three patients, the dose of erlotinib was
reduced to two third of the standard dose with less skin
toxicity and less subjective toxicity. However, the minimal
effective dose has yet to be determined in patients with EGFR
tyrosine kinase mutations. We demonstrated in an earlier
report that dose reduction to even one third of the standard
dose may result in tumor regression.8 Therefore, it might be
worthwhile to evaluate whether the maximally tolerable dose
of erlotinib, as found in early studies, is also needed in
patients with activating mutations. With respect to the like-
lihood of prolonged treatment in these cases and therefore
occurrence of the described side effects, it might be worth-
while to evaluate its efficacy at a lower dose.
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